The Nevada Assembly’s Legislative Operations and Elections Committee has passed a Senate-approved resolution urging U.S. Congress to reschedule certain psychedelics and increase federal research.
Nevada State Capitol Building.
Senate Joint Resolution 10 was given approval by the Senate last month. With approval through the Legislative Operations and Elections Committee, it now advances to a vote of the full Assembly.
The resoltion urges Congress to reschedule psychedelic compounds such as psilocybin, MDMA, DMT, ibogaine, and mescaline, and increase federal support for research into their use as treatments for conditions such as PTSD, treatment-resistant depression, anxiety, substance use disorder, and chronic pain.
Backed by 27 lawmakers from both chambers, the resolution cites a growing body of evidence from clinical trials and academic research conducted at institutions including Johns Hopkins, Stanford, and Yale. It also notes the FDA’s designation of several psychedelic treatments as “Breakthrough Therapies,” reflecting their potential efficacy and safety when administered in medical settings.
SJR 10 calls on Congress and federal agencies to increase funding, streamline research approvals, and move these substances to a more appropriate schedule under the Controlled Substances Act. It also urges legal protections for those operating in accordance with state psychedelic laws and supports expanded access under the federal Right to Try Act.
The resolution also encourages continued psychedelic research at Nevada-based institutions as part of a broader strategy to address the state’s mental health challenges through emerging therapies.
